SCN1A相关癫痫早期诊断预测模型的开发与验证
这项回顾性多中心队列研究纳入1018例SCN1A阳性患者,开发并验证了结合SCN1A遗传评分与癫痫起病年龄的预测模型,用于区分Dravet综合征与GEFS+。该模型在训练队列AUC为0.89,在两个独立验证队列AUC分别为0.94和0.92,有助于预后咨询和早期启动精准治疗。
要点
- SCN1A遗传评分高和起病年龄小均与Dravet综合征相关(p<0.001)。
- 联合SCN1A遗传评分与起病年龄的模型区分Dravet综合征与GEFS+的AUC为0.89,优于其他模型。
- 该模型在验证队列1和2中AUC分别为0.94和0.92,可辅助预后咨询和早期精准治疗决策。
核心结论
- 该预测模型可在疾病起病时客观估计患儿将发展为Dravet综合征还是GEFS+,辅助临床医生进行预后咨询和早期启动精准治疗的决策。
研究设计与样本
- 回顾性多中心队列研究,纳入2001年3月至2020年6月连续转诊接受基因检测的SCN1A阳性Dravet综合征和GEFS+患者,共1018例。
- 使用训练队列开发多个预测模型,并在2个独立盲法验证队列中验证。
主要发现
- Dravet综合征频率在训练队列为616/743(83%),验证队列1为147/203(72%),验证队列2为60/72(83%)。
- SCN1A遗传评分高(133.4 [SD 78.5] vs 52.0 [SD 57.5];p < 0.001)和起病年龄小(6.0 [SD 3.0] vs 14.8 [SD 11.8]个月;p < 0.001)均与Dravet综合征 vs GEFS+相关。
- 联合SCN1A遗传评分和起病年龄模型区分Dravet综合征与GEFS+的AUC为0.89(95% CI 0.86-0.92),优于所有其他模型(AUC 0.79-0.85;p < 0.001)。
- 模型性能在验证队列1(AUC 0.94 [95% CI 0.91-0.97])和验证队列2(AUC 0.92 [95% CI 0.82-1.00])中均得到重复。
关键数值与推荐
- 联合SCN1A遗传评分和起病年龄模型区分Dravet综合征与GEFS+的AUC为0.89(95% CI 0.86-0.92)。
- 验证队列1的AUC为0.94(95% CI 0.91-0.97),验证队列2的AUC为0.92(95% CI 0.82-1.00)。
- 本研究提供II级证据,表明联合SCN1A遗传评分和起病年龄模型可区分Dravet综合征与其他GEFS+表型。
临床怎么用
- 该预测模型可在疾病起病时客观估计患儿将发展为Dravet综合征还是GEFS+,辅助临床医生进行预后咨询和早期启动精准治疗的决策。
- 模型可通过网址http://scn1a-prediction-model.broadinstitute.org/获取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Pathogenic variants in the neuronal sodium channel α1 subunit gene (SCN1A) are the most frequent monogenic cause of epilepsy. Phenotypes comprise a wide clinical spectrum, including severe childhood epilepsy; Dravet syndrome, characterized by drug-resistant seizures, intellectual disability, and high mortality; and the milder genetic epilepsy with febrile seizures plus (GEFS+), characterized by normal cognition. Early recognition of a child's risk for developing Dravet syndrome vs GEFS+ is key for implementing disease-modifying therapies when available before cognitive impairment emerges. Our objective was to develop and validate a prediction model using clinical and genetic biomarkers for early diagnosis of SCN1A-related epilepsies. METHODS: We performed a retrospective multicenter cohort study comprising data from patients with SCN1A-positive Dravet syndrome and patients with GEFS+ consecutively referred for genetic testing (March 2001-June 2020) including age at seizure onset and a newly developed SCN1A genetic score. A training cohort was used to develop multiple prediction models that were validated using 2 independent blinded cohorts. Primary outcome was the discriminative accuracy of the model predicting Dravet syndrome vs other GEFS+ phenotypes. RESULTS: A total of 1,018 participants were included. The frequency of Dravet syndrome was 616/743 (83%) in the training cohort, 147/203 (72%) in validation cohort 1, and 60/72 (83%) in validation cohort 2. A high SCN1A genetic score (133.4 [SD 78.5] vs 52.0 [SD 57.5]; p < 0.001) and young age at onset (6.0 [SD 3.0] vs 14.8 [SD 11.8] months; p < 0.001) were each associated with Dravet syndrome vs GEFS+. A combined SCN1A genetic score and seizure onset model separated Dravet syndrome from GEFS+ more effectively (area under the curve [AUC] 0.89 [95% CI 0.86-0.92]) and outperformed all other models (AUC 0.79-0.85; p < 0.001). Model performance was replicated in both validation cohorts 1 (AUC 0.94 [95% CI 0.91-0.97]) and 2 (AUC 0.92 [95% CI 0.82-1.00]). DISCUSSION: The prediction model allows objective estimation at disease onset whether a child will develop Dravet syndrome vs GEFS+, assisting clinicians with prognostic counseling and decisions on early institution of precision therapies (http://scn1a-prediction-model.broadinstitute.org/). CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that a combined SCN1A genetic score and seizure onset model distinguishes Dravet syndrome from other GEFS+ phenotypes.
引用
- Brunklaus A, Pérez-Palma E, Ghanty I, et al. Development and Validation of a Prediction Model for Early Diagnosis of SCN1A-Related Epilepsies. Neurology. 2022. PMID: 35074891. doi:10.1212/WNL.0000000000200028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。